Unlock the Past, Preserve the Future: Virtual Worlds Museum™ Brings Together Digital Realms Under One Roof
The Virtual Worlds Museum™ explores the history of digital worlds, spanning from its origins in early text-based platforms to the cutting-edge virtual reality (VR) and video game environments that are actively being developed today.
" Our mission is to create a comprehensive archive that not only documents but also celebrates the innovations and communities that have shaped virtual worlds," said Julian Reyes, Founder and Director of the Virtual Worlds Museum™. "By participating in this campaign, backers will become a part of a movement that safeguards the history of these digital realms and supports our efforts to make it accessible to all and enjoyable by everyone."
Key Highlights of the Museum
• Comprehensive Digital Exhibits – Interactive exhibits covering the full spectrum of virtual environments, from WebXR experiences to immersive VR spaces like VRChat and Horizon Worlds.
• Immersive and Educational Experience – Each exhibit combines multimedia content, timelines, and interactive elements, allowing users to explore and engage with the evolution of virtual spaces.
• Support for Discontinued Worlds – A specialized exhibit, ' Sunset Worlds,' dedicated to preserving the memory of discontinued platforms such as AltspaceVR and High Fidelity, ensuring their legacy is not forgotten.
• Future Development – By supporting the campaign, backers can help shape the museum's future, bringing to life planned exhibits on video game worlds, VR worlds, and more.
• Expansive Knowledge Hub – From the Spotlight video series to a dedicated Wiki for virtual worlds, and an XR resources center, the Virtual Worlds Museum offers a growing library of educational content and tools, empowering users to delve deeper into the cultural and technological impact of digital environments.
Exclusive Partnership with TRIPP
Thanks to a special partnership with TRIPP, an award-winning digital wellness company creating transformative, immersive experiences for relaxation, focus, and productivity, the Virtual Worlds Museum™ is offering 30 one-year subscriptions to the TRIPP VR meditation experience as a special reward for backers. This collaboration highlights the museum's commitment to not only preserving the past but also embracing the future of digital experiences that enhance well-being and mindfulness.
The campaign also offers unique rewards for backers, including exclusive access to future immersive experiences. With the rise of the metaverse and digital platforms becoming integral to everyday life, the Virtual Worlds Museum™ is committed to documenting these transformations and educating the public about their cultural significance.
With the backing of this campaign, the museum will expand its current offerings, adding new exhibits that delve into the development, influence, and community impact of these virtual spaces.
To learn more about the museum or to support their campaign, visit the Virtual Worlds Museum™ Kickstarter page at https://www.kickstarter.com/projects/1474914332/virtual-worlds-museum
Media Contact
Company Name: Virtual Worlds Museum™
City: San Francisco
State: California
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
RepTrak Appoints Thierry D'Hers and Catherine Hernandez-Blades to Board of Directors
BOSTON, Aug. 12, 2025 /CNW/ --The RepTrak Company™, the world's leading provider of reputation intelligence, proudly announces the appointment of Thierry D'Hers and Catherine Hernandez-Blade s to its Board of Directors. These strategic appointments underscore RepTrak's commitment to scaling its reputation intelligence suite with cutting-edge technologies, AI-driven insights, and product innovation. Thierry D'Hers brings more than two decades of experience in product innovation, engineering leadership, and advisory roles. He is most known for his foundational role at Tableau, where he helped scale the company's data visualization platform, PowerBI, into a global business intelligence leader. Most recently, he served as Chief Product & Engineering Officer at Vivun. D'Hers has also advised several tech organizations including Pigment, Radar, Indico Labs, and Headwaters Economics — holding strategic roles in both enterprise and mission-driven technology ventures. "RepTrak is uniquely positioned at the intersection of technology, data, and trust," said D'Hers. "I'm excited to join the Board at a time when innovation and AI are reshaping how organizations manage stakeholder perception. I look forward to aiding the growth of the world's most powerful reputation intelligence platform." Catherine Hernandez-Blades Catherine Hernandez-Blades holds a distinguished track record across the financial services, defense, aerospace, technology, and government sectors. She currently serves as an independent board director for CoreCivic, Inc., where she sits on the Nominating & Governance and Risk Committees. Previously, she held C-suite roles at three Fortune 500 companies: Chief Marketing and Communications Officer at SAIC, Aflac, and Flex. In addition, she is an EMMY® winner, Cannes Lions recipient, Forbes Top 50 Global CMO, and the first and only American recipient of the Relations 4 the Future medal at Davos. "Having relied on RepTrak's products and services for over a decade across multiple Fortune 500 companies, I can personally attest to the platform's immense value. It not only quantifies the business impact driven by teams but also plays a crucial role in strategic decision-making — extending its influence to the entire C-suite and Board of Directors. I'm particularly excited about the innovative new products in development and am delighted to join RepTrak's board." Fueling Product and Platform Evolution These appointments reflect a deliberate move to accelerate the evolution of RepTrak's recently launched platform, Compass™ — deepening its technology, product, governance, and communications expertise. D'Hers and Hernandez-Blades bring strengths that will help guide RepTrak through its next phase of growth and innovation. "Thierry and Catherine bring distinct and deeply aligned expertise to RepTrak. Thierry's product and AI leadership, paired with Catherine's global reputation leadership, governance insight, and ESG acumen, position us to serve clients with sharper intelligence, deeper trust, and greater value than ever before. We are proud to welcome them both to the Board" says Mark Sonders, CEO of The RepTrak Company. About The RepTrak Company The RepTrak Company is the world's premier provider of reputation data and insights, helping businesses harness reputation intelligence to secure competitive advantage. RepTrak's predictive insights enable subscribers to safeguard business value, optimize ROI, and amplify their positive societal impact. Combining advanced metrics with dedicated reputation advisors, RepTrak delivers actionable analyses that align business goals with stakeholder sentiment across global markets and diverse industries. Established in 2004, The RepTrak Company owns the world's largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit About RepTrak Compass Compass is the only truly integrated global solution for reputation intelligence — combining RepTrak's world-class Global Advisory expertise with AI-enabled navigation. Designed for today's dynamic stakeholder environment, Compass enables leaders to shift from measuring reputation to actively shaping it. RepTrak invites communications, corporate affairs, brand, and reputation leaders around the world to explore Compass — and see how it empowers them to lead reputation, not just report on it.
Cision Canada
11 hours ago
- Cision Canada
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies, including membrane chromatography and automated control systems, along with iterative enhancements to Process Analytical Technology (PAT). The WuXiUP™ automated continuous production platform will deliver greater value as it boosts manufacturing efficiency and product quality, enabling clients to accelerate the journey of their innovative therapies from development to commercialization. SHANGHAI, Aug. 12, 2025 /CNW/ -- WuXi Biologics ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its intensified perfusion culture process platform, WuXiUP™, has achieved end-to-end, fully automated continuous drug substance（DS）production at pilot scale. The automated continuous production platform will be deployed across the company's major GMP facilities, offering clients greater efficiency and flexibility to accelerate the journey of their innovative therapies from development to commercialization. By fully integrating an automated system, the continuous production platform enables non-stop 24/7 operation, which minimizes manual intervention, reduces quality risks, and enhances manufacturing efficiency. In upstream processes, WuXiUP TM has accomplished exceptional performance: 24 days of continuous cell culture yields a total output that exceeds 110 g/L, with a peak daily yield of 7.6 g/L. For downstream purification, WuXiUP™ incorporates a two-step, high-efficiency membrane chromatography system. Compared to traditional resin-based stationary phases, this technology enables faster mass transfer, delivering a 5- to 10-fold increase in productivity. To strengthen quality control throughout downstream continuous purification, WuXiUP™ employs advanced, iteratively improved Process Analytical Technology (PAT), which provides real-time monitoring and feedback on critical parameters in Harvested Clarified Cell Culture Fluid (HCCF), including protein purity, concentration, pH, and conductivity. When integrated with the automated closed-loop control system, the technology utilizes Residence Time Distribution (RTD) analysis to intelligently divert out-of-spec samples, significantly enhancing manufacturing procedure control. Dr. Chris Chen, CEO of WuXi Biologics, commented: "The WuXiUP™ platform has already proved its technical maturity and viability in commercial manufacturing. And now it has reached another significant milestone: accomplishing fully automated continuous DS production at pilot scale. Such achievements underscore WuXi Biologics' steadfast dedication to furthering technological innovation, and advancing the standards for digitalization and automation in biopharmaceutical R&D and manufacturing — both of which are critical capabilities to improve quality and accelerate timelines. With our deep technical expertise and extensive track record, WuXi Biologics remains committed to enabling our global clients to speed drug development more efficiently, benefiting patients worldwide." About WuXiUP TM WuXiUP TM is an intensified perfusion culture process developed as a next-generation biomanufacturing solution that provides high-yield, high-quality drug products while being highly flexible and cost-effective. Compared to traditional fed-batch and perfusion processes, WuXiUP TM enables the manufacturing of diverse pharmaceutical proteins, including mAb, bispecific antibody, fusion protein, and other recombinant protein, with 5–20× higher productivity. This performance advantage is particularly notable when scaling to 1,000–2,000 L using single-use bioreactors, where it achieves productivity levels comparable to those of traditional 10,000–20,000 L stainless steel bioreactors. The WuXiUP TM platform has enabled one molecule to receive BLA approval and 11 others to receive IND approvals.
Toronto Star
12 hours ago
- Toronto Star
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery and NanoPalm Ltd., a Saudi-based biotechnology company pioneering advanced patterned lipid nanoparticle (pLNP) delivery systems, today announced the signing of a non-binding Letter of Intent (LOI). The LOI outlines the intention to form a joint venture to co-develop novel small-molecule oncology therapeutics, beginning with loading Rakovina's dual-function PARP-HDAC inhibitor, kt3283, into Nano Palm's pLNP technology. The collaboration brings together two novel platforms: Rakovina's proprietary AI-enabled drug discovery engine, powered by an exclusive license to the proprietary Deep Docking™ platform, is capable of rapidly screening billions of molecules against validated cancer targets and predicting drug-like characteristics in silico, and NanoPalm's next-generation self-targeting pLNP delivery system, AI-designed to enhance the precision and efficacy of therapeutic delivery. Promising candidates discovered through Rakovina's platform and formulated with Nanopalm's pLNP technology will be validated through Rakovina's in-house pharmacology, toxicology, and in vivo models, creating a seamless path from in silico modeling to formulation to preclinical proof of concept.
